23 research outputs found
An emerging generation of endocrine therapies in breast cancer: a clinical perspective
Abstract Anti-estrogen therapy is a key component of the treatment of both early and advanced-stage hormone receptor (HR)-positive breast cancer. This review discusses the recent emergence of several anti-estrogen therapies, some of which were designed to overcome common mechanisms of endocrine resistance. The new generation of drugs includes selective estrogen receptor modulators (SERMs), orally administered selective estrogen receptor degraders (SERDs), as well as more unique agents such as complete estrogen receptor antagonists (CERANs), proteolysis targeting chimeric (PROTACs), and selective estrogen receptor covalent antagonists (SERCAs). These drugs are at various stages of development and are being evaluated in both early and metastatic settings. We discuss the efficacy, toxicity profile, and completed and ongoing clinical trials for each drug and highlight key differences in their activity and study population that have ultimately influenced their advancement
Clinical characteristics, demographics, and outcomes in hormone-receptor (HR+) positive metastatic breast cancer (MBC) patients treated with palbociclib.
ContinuousâInfusion Topotecan and Erlotinib: A Study in TopotecanâPretreated Ovarian Cancer Assessing Shed Collagen Epitopes as a Marker of Invasiveness
Diabetes and Metformin Association with Recurrence Score in a Large Oncotype Database of Breast Cancer Patients
Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer
A Unique Presentation of Occult Primary Breast Cancer with a Review of the Literature
We are reporting a case of a 34-year-old woman with occult primary breast cancer discovered after initially presenting with neurological symptoms. She was successfully treated with neoadjuvant chemotherapy followed by definitive axillary lymph node dissection and ipsilateral whole breast radiotherapy. The case presented is unique due to the rarity of occult primary breast cancer, especially in light of her initial confounding neurological signs and symptoms, which highlights the importance of careful staging
Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases.
J Clin Oncol 2014 Oct 1; 32(28):3204-5